Laninamivir octanoate

Base Information

• Chemical Name: Laninamivir octanoate
• CAS No.: 203120-46-1
• Molecular Formula: C21H36N4O8
• Molecular Weight: 472.53
• UNII: E026V904RL
• DSSTox Substance ID: DTXSID001314719
• Nikkaji Number: J2.812.195D
• Wikidata: Q27276692
• Metabolomics Workbench ID: 152971
• ChEMBL ID: CHEMBL467058
• Mol file: 203120-46-1.mol

Synonyms:5-(acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid;laninamivir;laninamivir octanoate;laninamivir octanoate hydrate;laninamivir octanoate monohydrate;laninamivir trifluoroacetate;R 125489;R-125489;R125489

Chemical Property of Laninamivir octanoate

Chemical Property:

• PKA: 3.80±0.70(Predicted)
• PSA: 193.29000
• Density: 1.35
• LogP: 1.57150
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility.: DMSO (Slightly), Methanol (Very Slightly)
• XLogP3: 0.4
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 15
• Exact Mass: 472.25331412
• Heavy Atom Count: 33
• Complexity: 723

Purity/Quality:

99% ^*data from raw suppliers

Laninamivir octanoate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: CCCCCCCC(=O)OCC(C(C1C(C(C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O
• Isomeric SMILES: CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O
• Recent ClinicalTrials: A Multinational Phase III Study of CS-8958 (MARVEL)
• Recent EU Clinical Trials: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps? Dry Powder Inhaler in Adults with Symptomatic Influenza A or B Infection
• Recent NIPH Clinical Trials: The special drug use surveillance of INAVIR for inhalation suspension set (Safety evaluation in pediatric patients under five years old)
• Uses: Laninamivir Laninamivir (L174000) prodrug; a novel long-acting neuraminidase inhibitor.
• Clinical Use: Laninamivir octanote, a prodrug of a potent neuraminidase inhibitor (LANI), was approved and launched in 2010 in Japan for the treatment of influenza A and influenza B. This ester prodrug of a potent neuraminidase inhibitor was designed to permeate from the lung tissue to the plasma and then hydrolyze at such a rate to reveal the active form (laninamivir) as a long-acting therapeutic agent. Neuraminidase cleaves the glycosidic linkages of neuraminic acids which are responsible for binding new viruses to infected cells, thereby allowing viruses to release and infect other cells. Neuraminidase is essential for the replication of all influenza viruses. Like other neuraminidase inhibitors, laninamivir octanoate is a sialic acid analogue which is structurally similar to zanamivir, differing only by changing one of the hydroxy groups with a methyl ether substitution on the triol side chain. Laninamivir is administered via an inhalable formulation (20 mg, dry powder inhaler) and results from clinical trials of the drug have demonstrated that a single inhaled dose is as effective as a 5-day course of oseltamivir for treatment of influenza.